Background: Recent studies with intravenous (i.v.) application of ketamine show remarkable but short-term success in patients with MDD. Studies in patients with chronic pain have used different ketamine applications for longer time periods. This experience may be relevant for psychiatric indications.
Aims: To review the literature about the dosing regimen, duration, effects and side-effects of oral, intravenous, intranasal and subcutaneous routes of administration of ketamine for treatment-resistant depression and pain.
Method: Searches in PubMed with the terms 'oral ketamine', 'depression', 'chronic pain', 'neuropathic pain', 'intravenous ketamine', 'intranasal ketamine' and 'subcutaneous ketamine' yielded 88 articles. We reviewed all papers for information about dosing regimen, number of individuals who received ketamine, number of ketamine days per study, results and side-effects, as well as study quality.
Results: Overall, the methodological strength of studies investigating the antidepressant effects of ketamine was considered low, regardless of the route of administration. The doses for depression were in the lower range compared with studies that investigated analgesic use. Studies on pain suggested that oral ketamine may be acceptable for treatment-resistant depression in terms of tolerability and side-effects.
Conclusions: Oral ketamine, given for longer time periods in the described doses, appears to be well tolerated, but few studies have systematically examined the longer-term negative consequences. The short- and longer-term depression outcomes as well as side-effects need to be studied with rigorous randomised controlled trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1192/bjp.bp.115.165498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples.
Basic Clin Pharmacol Toxicol
February 2025
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating studies of the latter. Up to 138 NPS were retrospectively identified using liquid chromatography-high resolution mass spectrometry data from all 34 183 oral fluid drug samples collected in one Swedish health care region 2019-2020 representing 9468 psychiatric and addiction care patients. In total, 618 findings representing 58 NPS were detected in 481 samples from 201 patients.
View Article and Find Full Text PDFComparative Analysis of Preoperative Sedation Modalities: Oral Midazolam and Ketamine Versus Chloral Hydrate and Meperidine in Pediatric Tonsillectomy - A Randomized Clinical Trial.
Turk Arch Otorhinolaryngol
January 2025
Shiraz University of Medical Sciences, Anesthesiology and Critical Care Research Center, Shiraz, Iran.
Objective: A pre-anesthetic medication that is ideal for pediatric patients undergoing tonsillectomy should alleviate pediatric anxiety, facilitate the smooth induction of anesthesia, and have an analgesic effect for postoperative care. This study compared the effectiveness of an oral combination of midazolam and ketamine (MK) with an oral combination of chloral hydrate and meperidine (CM) as premedication in pediatric patients undergoing tonsillectomy.
Methods: This double-blind clinical trial study was conducted with 68 pediatric patients scheduled to undergo tonsillectomy.
Proteomic patterns associated with ketamine response in major depressive disorders.
Cell Biol Toxicol
January 2025
Research Institute, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, 510370, China.
Background: Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment.
View Article and Find Full Text PDFChelidonic acid abrogates oxidative stress and memory dysfunction in experimental aging rats.
Turk J Biol
October 2024
Neuropyschopharmacology Application and Research Center, Üsküdar University, İstanbul, Turkiye.
Background/aim: In an aging model established using male Wistar albino rats via the administration of D-galactose (D-gal), the aim of this study was to examine the effects of chelidonic acid (CA) on cognitive function and the levels of glutathione (GSH), malondialdehyde (MDA), total antioxidant status (TAS), and brain-derived neurotrophic factor (BDNF).
Materials And Methods: Thirty-two, three-month-old Wistar albino male rats (n = 8) were divided into four groups, as the control (C) group, CA group (2 mg/kg of CA via oral gavage), D-gal group (150 mg/kg of D-gal, subcutaneously), and D-gal + CA group (150 mg/kg of D-gal and 2 mg/kg of CA). Following overnight fasting, the 10-week trial was concluded with intramuscular injections of anesthetic drugs xylazine (8-10 mg/kg) and ketamine (80-100 mg/kg), and subsequently, the collection of cardiac blood.
Mucositis Pain and Its Temporal Relationship to White Cell Count.
Paediatr Anaesth
January 2025
Department of Anaesthesia, Starship Children's Hospital, Auckland, New Zealand.
Article Synopsis
- The study investigates the link between pain scores and white blood cell counts in children with mucositis due to immunosuppression from cancer treatments.
- The research involved 50 children, measuring pain relief alongside changes in white blood cell counts and the effects of opioid and ketamine analgesia.
- Findings revealed a significant delay of about 0.29 days for pain to respond to increasing white blood cell counts, highlighting the dominance of biological recovery over analgesic intervention in pain management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!